Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort

Journal of Adolescent Health

Volumn 29, Issue 3 SUPPL. 1, 2001, Pages 123-129

  Wilson, Craig M ^a   Ellenberg, Jonas H ^b   Sawyer, Mary K ^c   Belzer, Marvin ^d   Crowley Nowick, Peggy A ^e   Puga, Ana ^f   Futterman, Donna C ^g   Peralta, Ligia ^h  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b WESTAT   (United States)

^c EMORY UNIVERSITY   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f Children's Diagnostic and Treatment Center   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF MARYLAND   (United States)

Author keywords

Adolescents; HBV vaccine; HIV infection

Indexed keywords

HEPATITIS B VACCINE;

ADOLESCENCE; ADOLESCENT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEXUAL BEHAVIOR; T LYMPHOCYTE;

ADOLESCENT; ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; ANTIGENS, DIFFERENTIATION; CD8-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HIV INFECTIONS; HLA-DR ANTIGENS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NAD+ NUCLEOSIDASE; SEROLOGIC TESTS;

EID: 0034870146     PISSN: 1054139X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1054-139X(01)00278-6     Document Type: Article

References (43)

1. Hepatitis B; Evolving epidemiology and implications for control
2. Prevalence of hepatitis B virus infection in the United States; The National Health and Nutrition Examination Surveys, 1976 through 1994
3. Surveillance and prevention of hepatitis B virus transmission
4. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus
5. Immunogenicity of hepatitis B vaccine in human immunodeficiency virus-infected children
6. Response to hepatitis B immunization by infants exposed to HIV
7. Hepatitis B vaccination in infants of mothers infected with human immunodeficiency virus
8. Impaired response to hepatitis B vaccine in HIV infected children
9. + lymphocyte count and vaccination schedule
10. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals
11. Immune response to hepatitis B vaccine in parenteral drug abusers
12. Diminished response to recombinant hepatitis B vaccine in homosexual men with HIV antibody; An indicator of poor prognosis
13. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men
14. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination
15. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine
16. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons
17. The REACH project of the adolescent medicine HIV/AIDS research nNetwork; Design, methods, and selected characteristics of participants
18. The REACH (Reaching for Excellence in Adolescent Care and Health) Project; Study design, methods, and population profile
19. Peripheral blood mononuclear cell markers in antiretroviral therapy-naive HIV-infected and high risk seronegative adolescents
20. T lymphocyte subsets in HIV-infected and high risk HIV-uninfected adolescents-Retention of naive T-cells in HIV infected
21. + T cell counts and HIV type 1 viral loads in untreated, infected adolescents
22. -DR antigens
23. + cell levels
24. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine
25. Response to hepatitis B virus vaccine in haemodialysis patients; Influence of malnutrition and its importance as a risk factor for morbidity and mortality
26. The prevalence of anergy in human immunodeficiency virus infected adolescents and the association of delayed-type hypersensitivity with subject characteristics
27. Statistical aspects of the analysis of data from retrospective studies of disease
28. Confidence interval for the ratio of two binomial proportions
29. + cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression
30. Randomized, single-blind comparison of the immunogenicity and reactogenicity of 20 μg and 10 μg doses of hepatitis B vaccine in adolescents
31. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in adolescents
32. Two-dose combined vaccination against hepatitis A and B in healthy subjects aged 11-18 years
33. Hepatitis B vaccine administered to children and adolescents at yearly intervals
34. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10 year old children
35. Alternate two-dose hepatitis B vaccination schedule for adolescents aged 11- 15 years
36. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
37. Predictors of time to completion of the hepatitis B vaccine series among adolescents
38. Compliance of hepatitis B vaccination in patients presenting to a teenage clinic
39. Hepatitis B vaccine series compliance in adolescents
40. Seroprevalence of hepatitis B, hepatitis C, and human cytomegalovirus among HIV-infected and high risk uninfected adolescents; Findings of the Reaching for Excellence in Adolescent Care and Health study (REACH)
41. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load